Literature DB >> 6569851

The combination of pivmecillinam and pivampicillin in the treatment of enteric fever.

D Tanphaichitra, S Srimuang, P Chiaprasittigul, P Menday, O E Christensen.   

Abstract

Thirty-nine patients with acute enteric fever received the fixed-dose oral combination of pivmecillinam/pivampicillin. Thirty-seven (95%) subjects responded satisfactorily. No relapses or persistent faecal excretion of salmonellae were seen in the 29 patients followed up for 2 to 19 weeks. The treatment was well tolerated, no side-effects being recorded. In vitro studies revealed a synergistic interaction between mecillinam and ampicillin against isolates of Salmonella paratyphi A.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6569851     DOI: 10.1007/bf01645219

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  7 in total

1.  Chloramphenicol-resistant typhoid fever in Vietnam associated with R factor.

Authors:  T Butler; N N Linh; K Arnold; M Pollack
Journal:  Lancet       Date:  1973-11-03       Impact factor: 79.321

2.  The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever.

Authors:  D Tanphaichitra; A Bussayanond; O Christensen
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

3.  Randomised, comparative trial of mecillinam, mecillinam/ampicillin and chloramphenicol in the treatment of enteric fever.

Authors:  B M Limson; M T Mendoza; E Liwanag; O E Christensen; P Menday
Journal:  J Antimicrob Chemother       Date:  1982-05       Impact factor: 5.790

4.  Chloramphenicol resistance in the typhoid bacillus.

Authors:  E S Anderson; H R Smith
Journal:  Br Med J       Date:  1972-08-05

5.  The combination of pivmecillinam and pivampicillin compared to co-trimoxazole in the treatment of enteric fever.

Authors:  D Tanphaichitra; A Bussayanond; O Christensen
Journal:  Infection       Date:  1982       Impact factor: 3.553

6.  Pivmecillinam plus pivampicillin in urinary tract infections. A double-blind comparison with pivmecillinam alone in hospitalized patients.

Authors:  E P Saltvedt; R Schøyen
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

7.  Double-blind comparison of pivmecillinam plus pivampicillin ('Miraxid') with pivampicillin alone in chronic bronchitis: a Danish multi-centre study.

Authors:  N Bukh
Journal:  Pharmatherapeutica       Date:  1983
  7 in total
  4 in total

1.  Efficacy of the combination pivampicillin/pivmecillinam compared to placebo in the treatment of convalescent carriers of nontyphi Salmonella.

Authors:  B Svenungsson; E Ekwall; H B Hansson
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

2.  Serum bactericidal activity of two newer quinolones against Salmonella typhi compared with standard therapeutic regimens.

Authors:  M Trautmann; B Krause; D Birnbaum; J Wagner; V Lenk
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

3.  Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections.

Authors:  D Tanphaichitra; S Sahaphong; S Srimuang
Journal:  Infection       Date:  1986       Impact factor: 3.553

4.  Evaluation of a Smartphone Decision-Support Tool for Diarrheal Disease Management in a Resource-Limited Setting.

Authors:  Farhana Haque; Robyn L Ball; Selina Khatun; Mujaddeed Ahmed; Saraswati Kache; Mohammod Jobayer Chisti; Shafiqul Alam Sarker; Stace D Maples; Dane Pieri; Teja Vardhan Korrapati; Clea Sarnquist; Nancy Federspiel; Muhammad Waliur Rahman; Jason R Andrews; Mahmudur Rahman; Eric Jorge Nelson
Journal:  PLoS Negl Trop Dis       Date:  2017-01-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.